Hoth Therapeutics (HOTH)
(Delayed Data from NSDQ)
$0.85 USD
-0.03 (-3.17%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $0.86 +0.01 (1.71%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.85 USD
-0.03 (-3.17%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $0.86 +0.01 (1.71%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Zacks News
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
by Zacks Equity Research
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
by Zacks Equity Research
Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.
Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine
by Zacks Equity Research
Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.